These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17190373)

  • 41. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.
    Antonijoan R; García-Gea C; Puntes M; Pérez J; Esbrí R; Serra C; Fortea J; Barbanoj MJ
    Clin Ther; 2007 May; 29(5):814-822. PubMed ID: 17697901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Flushing and other dermatologic adverse events associated with extended-release niacin therapy.
    Guyton JR; Simmons PD
    J Clin Lipidol; 2009 Apr; 3(2):101-8. PubMed ID: 21291799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
    Goldberg AC
    Am J Cardiol; 1998 Dec; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
    Chen F; Maccubbin D; Yan L; Sirah W; Chen E; Sisk CM; Davidson M; Blomqvist P; McKenney JM
    Int J Cardiol; 2013 Jul; 167(1):225-31. PubMed ID: 22305632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
    J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Important considerations for treatment with dietary supplement versus prescription niacin products.
    Backes JM; Padley RJ; Moriarty PM
    Postgrad Med; 2011 Mar; 123(2):70-83. PubMed ID: 21474895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study.
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E;
    Curr Med Res Opin; 2006 Feb; 22(2):417-25. PubMed ID: 16466614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
    Bays HE; Ballantyne C
    Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
    Kamal-Bahl S; Watson DJ; Ambegaonkar BM
    Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of flushing due to niacin and abolition of these effects.
    Sood A; Arora R
    J Clin Hypertens (Greenwich); 2009 Nov; 11(11):685-9. PubMed ID: 19878384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease.
    Mason CM; Doneen AL
    J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.